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Abstract
Background
The 13-valent pneumococcal conjugate vaccine (PCV13) was licensed based on the results
of immunogenicity studies and correlates of protection derived from randomized clinical tri-
als of the 7-valent conjugate pneumococcal vaccine. We assessed the vaccination effective-
ness (VE) of the PCV13 in preventing invasive pneumococcal disease (IPD) in children
aged 7–59 months in a population with suboptimal vaccination coverage of 55%.
Methods
The study was carried out in children with IPD admitted to three hospitals in Barcelona
(Spain) and controls matched by hospital, age, sex, date of hospitalization and underlying
disease. Information on the vaccination status was obtained from written medical records.
Conditional logistic regression was made to estimate the adjusted VE and 95% confidence
intervals (CI).
Results
169 cases and 645 controls were included. The overall VE of1 doses of PCV13 in prevent-
ing IPD due to vaccine serotypes was 75.8% (95% CI, 54.1–87.2) and 90% (95% CI, 63.9–
97.2) when2 doses before 12 months, two doses on or after 12 months or one dose on or
after 24 months, were administered. The VE of1 doses was 89% (95% CI, 42.7–97.9)
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against serotype 1 and 86.0% (95% CI, 51.2–99.7) against serotype 19A. Serotype 3
showed a non-statistically significant effectiveness (25.9%; 95% CI, -65.3 to 66.8).
Conclusions
The effectiveness of1 doses of PCV13 in preventing IPD caused by all PCV13 serotypes
in children aged 7–59 months was good and, except for serotype 3, the effectiveness of1
doses against the most frequent PCV13 serotypes causing IPD was high when considered
individually.
Introduction
Streptococcus pneumoniae continues to be a leading cause of morbidity and mortality in per-
sons of all ages and the leading cause of bacterial childhood pneumonia and death in children
worldwide. Pneumococcal infections include invasive pneumococcal diseases (IPD) such as
meningitis, bacteremia and bacteremic pneumonia. In 2015, the estimated number of deaths
due to pneumonia worldwide in children aged<5 years was 921,000, and the mortality rate
was 6.59 per 1,000 live births [1].
There are currently 97 recognized S. pneumoniae serotypes [2], but their distribution varies
with age and geographical region. The continued incidence and severity of pneumococcal dis-
ease, and the increasing prevalence of strains of pneumococci with reduced antimicrobial sus-
ceptibility underline the need for research into the prevention of pneumococcal infections.
Pneumococcal protein conjugate vaccines have been designed and developed to prevent
invasive and non-invasive pneumococcal disease caused by S. pneumoniae. The first licensed
vaccine, the 7-valent pneumococcal conjugate vaccine (PCV7) contained polysaccharides of
seven pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F and 23F), which were the most fre-
quent IPD-causing serotypes at the end of the last century in the United States. In 2009–2010,
two other conjugate vaccines were licensed to respond to emerging serotypes: 10-valent pneu-
mococcal conjugate vaccine (PCV10) (containing serotypes 1, 5 and 7F in addition to the
PCV7 serotypes) and PCV13 (containing serotypes 3, 6A and 19A in addition to the PCV10
serotypes) [3].
The PCV13 vaccine, unlike the PCV7 vaccine, was licensed based on the results of immunoge-
nicity studies for the added serotypes and the correlates of protection derived from randomized
clinical trials of the PCV7 vaccine [3, 4]. Therefore, continuing observational epidemiological
studies (case-control and indirect cohort studies) are required to assess the protective value of the
vaccine under normal, non-experimental administration.
The WHO recommends three primary doses or, alternatively, two primary doses plus a
booster after considering locally-relevant factors including the epidemiology of pneumococcal
disease, the likely coverage and the vaccine schedule of the vaccine doses [5].
Although the Vaccination Advisory Committee of the Spanish Association of Pediatrics has
recommended the routine administration of conjugate pneumococcal vaccines (PCV7 since
2003–2010 and, currently, PCV13) these vaccines were not financed by the Catalan Public
Health System until July 2016, except in children with selected risk factors, and were only avail-
able in the private sector. In Spain, the vaccine was not introduced into the recommended calen-
dar until January 2017, and there are no estimates of vaccination coverage. In the Madrid region,
PCV13 was introduced into the vaccination calendar in June 2010 but was later excluded from
2012 to 2015 for economic reasons. During the periods when the vaccine was included in the
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calendar, the coverage in children aged<2 years was 95% and during the years it was not
included, coverage ranged from 67% to 82% [6]. In Navarre, as in Catalonia, the vaccine was not
included in the immunization calendar and the coverage was 76% in 2011–2014 in children aged
<5 years [7]. In Catalonia, the coverage of PCV13 achieved in children aged<5 years in 2012–
2013 was estimated as 55% [8] and the coverage of PCV10 in children aged<2 years was esti-
mated as<4% [9].
Vaccination effectiveness (VE) against PCV13 serotypes requires field investigation because
changes in the distribution of serotypes can influence the overall VE. In Catalonia, the overall
incidence of IPD and the incidence in children aged<5 years decreased in 2010–2013 in rela-
tion to 2006–2009 but the distribution of most frequent serotypes changed [10]. Serotype 3,
which had been very infrequent previously [11], has been the most frequent serotype in recent
years [10,12] and several failures against IPD caused by this serotype in PCV13-vaccinated
children has been observed [8].
The objective of the study was to evaluate the VE of PCV13 against IPD caused by the dif-
ferent serotypes included in the vaccine under usual condition of administration in children
aged 7–59 months.
Methods
Data confidentiality and ethical aspects
No diagnostic tests were made or samples taken from any participant in addition to those
required by routine care. The study complies with the principles of the Declaration of Helsinki
and the legal structure in respect to international human rights and biomedicine and protec-
tion of personal data laws.
The Ethics Committee of Hospital Sant Joan de De´u approved the study. Informed consent
signed by parents or legal guardians was given for all participants (cases and controls). All data
were treated as confidential and records were accessed anonymously.
Study design
A matched case-control study was carried out in patients with IPD admitted to three pediatric
hospitals in Barcelona, Spain (Hospital de Nens, Hospital Sant Joan de De´u and Hospital Vall
d’Hebro´n). The estimated reference population aged<5 years of the three hospitals was
116,279, representing 30.4% of the whole population of this age group in Catalonia (382,507
children) [13]. Cases and controls were recruited between January 2012 and June 2016.
Selection of cases
Patients aged 7–59 months hospitalized for IPD were studied. IPD was defined as isolation by
culture of S. pneumoniae or DNA detection of the Lyt A gene and an additional capsular gene
of S. pneumoniae by real-time polymerase chain reaction (PCR) in any normally-sterile site
according to a previously reported method [14]. Strains isolated by culture were serotyped
using the Quellung reaction or dot blot by the National Centre for Microbiology, Majada-
honda, Madrid. Culture-negative and PCR-positive samples with a cycle threshold (Ct)>30
cycles were serotyped using a previously-described, real-time multiplex PCR technique [15].
PCR-positive samples with a Ct30 cycles were serotyped using sequential multiplex PCR
combined with fragment analysis and automated fluorescent capillary electrophoresis [16].
Children with IPD in whom serotyping of S. pneumoniae was not possible because the sample
was not available were excluded.
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Selection of controls
Four controls were selected for each case from patients attending the same hospitals for causes
other than IPD. Controls were matched by age (±6 months in patients aged <12 months and
±12 months in patients aged 12–59 months), sex, date of hospitalization of the case (±3
months) and underlying medical conditions [17], when present. Study investigators were
blinded to the vaccination status of all controls during selection.
Vaccination status of cases and controls
A case or control was considered vaccinated if this was recorded in the medical record, the vac-
cination card or the child’s health card. Cases and controls whose vaccination status could not
be determined were excluded. Any dose of PCV13 given after six weeks of age, at least four
weeks after the previous dose, and at least 15 days before the hospital admission date (cases) or
before the hospitalization date of the matched case (controls) was considered valid.
To assess the VE against all PCV13 serotypes, the vaccination status included only doses of
PCV13 and any child (case or control) who received PCV7, PCV10 or a mixture of either with
PCV13 was excluded from the analysis. To assess the VE against PCV13-non-PCV7 serotypes,
only doses of PCV13 were considered and any child who received only PCV7 or PCV10 was
excluded from the analysis.
Sociodemographic, clinical and epidemiological variables
The demographic and clinical variables recorded for each case were: age, sex, date of hospitali-
zation, clinical form, underlying medical conditions, antibiotic therapy, history of respiratory
infection in the 30 days before symptom onset and recurrent acute otitis media. Other epide-
miological variables recorded were: birth weight, day care or school attendance, house size,
number of cohabitants, siblings, parental smoking, parental education and influenza vaccina-
tion in the current season. The same variables were recorded for controls except for those
relating to IPD. All variables were collected using a single questionnaire for cases and controls
and there was an instruction manual to facilitate compliance.
Sample size
The sample size required was calculated using Schlesselman’s criteria [18]. Assuming a preva-
lence of a history of vaccination in controls of 47% [19], a VE of 80%, a bilateral α error of 0.05
(two-tailed), and a β error of 0.2, and supposing that 25% of cases would be caused by vaccine
serotypes (at present the figure is higher but vaccine serotypes are expected to decrease follow-
ing the introduction of PCV13), that four controls would be sought per case, and that children
aged 7–23 months and those aged 24–59 months would be analyzed separately, the minimum
number of cases required was estimated at 160 and the number of controls as 642.
Statistical analysis
Differences in demographic, clinical and epidemiological variables between cases and controls
were analyzed using the McNemar test for categorical variables and the paired t-test for con-
tinuous variables. A two-tailed distribution was assumed for all p-values.
To estimate the adjusted VE a multivariate analysis was performed using conditional logistic
regression. We introduced all demographic, clinical and epidemiological variables in the model
and obtained a final model using backward stepwise selection with a cut-off point of p<0.2.
Interactions between vaccination and other variables were assessed using the likelihood ratio
test in the conditional regression analysis. Independent variables were checked for collinearity
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using the variance inflation factor [20].
VE was calculated using the formula VE ¼ ð1   ORÞ  100:
Analyses were performed for PCV13 serotypes, PCV13-non-PCV 7 serotypes, and individual
serotypes according to the number of doses, schedule and age group. The analysis was per-
formed using the SPSS v24 statistical package and R v3.3.0 statistical software.
Results
During the study period, 180 cases of IPD were detected in patients aged 7–59 months, of
whom 169 were included. The remaining cases were excluded because no controls meeting the
study criteria were found (one case), or the sample for serotyping (seven cases) or the clinical
record (three cases) were not available. A total of 239 samples from the 169 patients were stud-
ied. Of these, 31 samples were negative and 208 were positive for PCR and/or culture. Of the
144 blood samples analyzed, 43 were positive for culture alone, 49 for PCR alone and 23 for
culture and PCR; of the 74 pleural fluid samples, 4 were positive for culture alone, 56 for PCR
alone and 13 for culture and PCR; of the 12 cerebrospinal fluid samples, 3 were positive for cul-
ture alone, 4 for PCR alone and 4 for culture and PCR; all 4 synovial fluid samples, 1 epidural
abscess sample and 1 otogenic abscess sample analyzed were positive for culture alone; 2 mas-
toid samples and 1 nasopharyngeal aspirate sample were positive for PCR alone. Cases with
nasopharyngeal aspirate and otogenic abscess samples also had positive blood samples. Of the
169 cases, 83 (49.1%) were diagnosed by PCR alone, 43 (25.4%) by culture alone and 43
(25.4%) by culture and PCR. The most frequent serotypes in the cases included were serotype
3 (24.3%), serotype 1 (11.2%), serotype 19 A (9.5%) and serotype 14 (7.1%). The distribution
of serotypes according to the receipt of any dose of PCV13 vaccine is shown in Fig 1. Serotype
3 was more frequent in the 24–59 months age group than in the 7–23 months age group
(75.6% vs. 24.4%, p = 0.01). The clinical manifestations of the cases were: complicated pneu-
monia including empyema, pleural effusion or necrotizing pneumonia (58.6% in all cases,
45.1% in children aged 7–23 months and 68.4% in children aged 24–59 months), uncompli-
cated pneumonia (15.4% in all cases, 14.1% in children aged 7–23 months and 16.3% in chil-
dren aged 24–59 months), occult bacteremia (10.6% in all cases, 16.9% in children aged 7–23
months and 6.1% in children aged 24–59 months), and meningitis (6.5% in all cases, 9.9% in
children aged 7–23 months and 4.1% in children aged 24–59 months). Other forms included
mastoiditis (3.0%), bone and joint infection (3.0%), septic shock (2.3%) and cellulitis (0.6%).
We included 645 matched controls attending the same hospitals due to causes other
than IPD. The demographic, epidemiologic and clinical characteristics of cases and con-
trols are shown in Table 1. The proportion of cases and controls who had received 1
doses of PCV13 were 44.4% and 63.6%, respectively. The underlying medical conditions
of cases and controls were: immunosuppressive therapy (4 cases and 9 controls), chronic
renal failure (1 case and 3 controls), chronic lung disease (1 case and 3 controls) and chr-
onic heart disease (2 cases and 2 controls). No interaction was found between vaccination
and the other variables. Crude and adjusted estimations of VE for all PCV13 serotypes and
all PCV13 serotypes, excluding serotype 3, according to age, number of doses and vaccina-
tion schedule is shown in Table 2. Table 3 summarizes the estimates of crude and adjusted
VE for PCV13-non-PCV7 serotypes, including and excluding serotype 3, according to age,
number of doses and vaccination schedule. The VE against individual serotypes 1, 3, 14
and 19A is shown in Table 4 (this could not be assessed for other serotypes due to the low
number of cases).
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Discussion
This matched case-control study carried out in children aged 7–59 months admitted to three
Catalonia pediatric hospitals has provided three main results. First, the overall VE of1 doses
of PCV13 in preventing IPD caused by vaccine serotypes is good (75.8%; 95% CI, 54.1–87.2)
and increases when2 doses before 12 months, two doses on or after 12 months or one dose
on or after 24 months, are administered (90%; 95% CI, 63.9–97.2). In the 24–59 months age
group, the latter schedule showed a non-significant effectiveness against IPD (83.5%; 95% CI,
-19.5 to 97.7), probably because serotype 3 was more frequent in this age group. Secondly, the
VE of1 doses against two previously-emergent serotypes in our geographical area was high:
89% (95% CI, 42.7–97.9) for serotype 1 and 86.0% (95% CI, 51.2–99.7) for serotype 19A, but
the VE of1 doses against serotype 3 showed a non-significant effectiveness (25.9%; 95% CI,
-65.3 to 66.8). Thirdly, the VE of1 doses against serotype 14 was the highest found (96.9%;
95% CI, 70.4–99.7), which is important because this serotype is a very frequent cause of IPD in
Catalonia [12].
Our results are similar to those obtained in observational studies carried out in other loca-
tions [7,21–27]. In case-control studies [7,21–26], the point estimate of VE against PCV13
serotypes ranges between the 77% (95% CI, 38–91) found by Miller et al. [21] in the United
Kingdom in children aged 2.5–24 months who received one dose on or after 12 months or at
least one dose before 12 months and one dose on or after 12 months and the 91% (95% CI, 61–
99) found by Van Der Linden et al.[23] in children aged<2 years who had received the com-
plete immunization schedule in Germany. In the study by Cohen et al. [26] in South Africa,
Fig 1. Distribution of serotypes of cases included in the study according to the receipt of any dose of PCV13 vaccinea. ONV = Other non-
PCV13 serotypes aAny child who received only PCV7 or PCV10 was excluded
https://doi.org/10.1371/journal.pone.0183191.g001
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Table 1. Characteristics of cases and controls.
Characteristic Cases Controls P value
(N = 169) (N = 645)
Age in months, median (range) 27 (7–59) 29 (7–71) 0.04
Age group 0.20
7–23 months 71 (42.0%) 252 (39.1%)
24–59 months 98 (58.0%) 393 (60.9%)
Sex 1.00
Female 64 (37.9%) 248 (38.4%)
Male 105 (62.1%) 397 (61.6%)
Underlying medical condition 1.00
Yes 8 (4.7%) 17 (2.6%)
No 161 (95.3%) 628 (97.4%)
Birth weight, median (range) 3.2 (0.8–5.6) 3.2 (0.62–5.0) 0.08
Breastfeeding 0.21
Yes 140 (82.8%) 508 (78.8%)
No 29 (17.2%) 137 (21.2%)
Day care or school attendance 0.01
Yes 120 (71.0%) 411 (63.7%)
No 49 (29.0%) 234 (36.3%)
Antibiotic treatment in previous month 0.71
Yes 26 (15.4%) 104 (16.1%)
No 143 (84.6%) 541 (83.9%)
Respiratory infection in previous month 0.51
Yes 96 (56.8%) 354 (54.9%)
No 73 (43.2%) 291 (45.1%)
Recurrent acute otitis media 0.26
Yes 24 (14.2%) 116 (18.0%)
No 145 (85.8%) 529 (82.0%)
House size (m2), median (range) 80 (40–400) 85 (40–500) 0.01
Cohabitants, median (range) 4 (2–10) 4 (1–11) 0.62
Siblings 0.41
Yes 95 (56.2%) 386 (59.8%)
No 74 (43.8%) 259 (40.2%)
Exposure to tobacco in the home 0.34
Yes 55 (32.5%) 233 (36.1%)
No 114 (67.5%) 412 (63.9%)
Head of the family working 0.33
Yes 151 (89.3%) 593 (91.9%)
No 18 (10.7%) 52 (8.1%)
Influenza vaccine in the current season 0.20
Yes 3 (1.8%) 24 (3.7%)
No 166 (98.2%) 621 (96.3%)
Educational level of parentsa 0.27
No or primary 16 (10.1%) 50 (8.0%)
Secondary or higher 143 (89.9%) 575 (92.0%)
1 dose of PCV13 (7–59 months) 75 (44.4%) 410 (63.6%) <0.01
7–23 months 38 (53.5%) 180 (71.4%) <0.01
(Continued )
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Table 1. (Continued)
Characteristic Cases Controls P value
(N = 169) (N = 645)
24–59 months 37 (37.8%) 230 (58.5%) <0.01
PCV13 = 13-valent pneumococcal conjugate vaccine
aThis information was not available for 10 cases and 20 controls
https://doi.org/10.1371/journal.pone.0183191.t001
Table 2. Crude and adjusted effectiveness of the 13-valent pneumococcal conjugate vaccination against IPD caused by PCV13 serotypes includ-
ing and excluding serotype 3 in the prevention of invasive pneumococcal disease in children aged 7–59 months according to vaccination sched-
ule, number of doses received and age.
Serotypes coverage, vaccination schedule and age
groups
Cases Vaccinated/
N (%)
Controls
Vaccinated/N (%)
Crude VE
(95% CI)
p value Adjusted VE
(95% CI)
p value
All PCV13 serotypesa
1 dose 29/85 (34.1%) 189/298 (63.4%) 69.4% (48.3–
81.9)
<0.001 75.8% (54.1–
87.2)
<0.001
7–23 months 10/31 (32.3%) 82/121 (67.8%) 75.1% (43.9–
88.9)
0.001 80.7% (45.3–
93.2)
0.002
24–59 months 19/54 (35.2%) 107/177 (60.5%) 64.4% (29.6–
82.0)
0.003 75.3% (45.4–
88.9)
0.001
2 doses before 12 months or 2 doses on or after 12
months or 1 dose on or after 24 months
13/69 (18.8%) 67/176 (38.1%) 65.9% (24.8–
84.5)
0.01 90.0% (63.9–
97.2)
<0.001
7–23 months 6/27 (22.2%) 51/90 (56.7%) 76.7% (36.6–
91.4)
0.004 92.8% (55.4–
98.8)
0.005
24–59 months 7/42 (16.7%) 16/86 (18.6%) 32.5%
(-127.7–80.0)
0.53 83.5% (-19.5–
97.7)
0.07b
2 doses before 12 months and 1 dose after 12
months
15/71 (21.1%) 116/225 (51.6%) 70.3% (42.2–
84.8)
<0.001 78.9% (52.8–
90.5)
<0.001
7–23 months 3/24 (12.5%) 31/70 (44.3%) 79.4% (22.1–
94.5)
0.02 91.2% (16.2–
99.9)
0.03
24–59 months 12/47 (25.5%) 85/155 (54.8%) 65.9% (26.0–
84.3)
0.01 73.4% (36.4–
88.9)
0.003
All PCV13 serotypes, excluding serotype 3a
1 dose 9/50 (18.0%) 112/175 (64.0%) 87.7% (72.3–
94.5)
<0.001 95.8% (84.0–
98.9)
<0.001
7–23 months 6/22 (2.7%) 63/86 (73.3%) 83.5% (55.5–
93.9)
<0.001 95.5% (54.5–
99.5)
0.01
24–59 months 3/28 (10.7%) 49/89 (55.1%) 92.8% (67.4–
98.4)
<0.001 97.1% (79.8–
99.6)
<0.001
2 doses before 12 months or 2 doses on or after 12
months or 1 dose on or after 24 months
5/46 (10.9%) 46/109 (42.2%) 83.9% (48.8–
95.0)
0.002 97.9% (75.3–
99.8)
0.002
7–23 months 4/20 (20.0%) 38/61 (62.3%) 80.7% (35.2–
94.2)
0.008 92.7% (35.3–
99.2)
0.02
24–59 months 1/26 (3.8%) 8/48 (16.7%) - - - -
2 doses before 12 months and 1 dose after 12
months
3/44 (6.8%) 63/126 (50.0%) 91.8% (71.9–
97.6)
<0.001 97.5% (83.9–
99.6)
<0.001
7–23 months 1/17 (5.9%) 25/48 (52.1%) 93.4% (45.4–
99.2)
0.01 96.9% (58.7–
99.8)
0.01
24–59 months 2/27 (7.4%) 38/78 (48.7%) 90.7% (57.6–
98.0)
0.002 95.1% (68.0–
99.3)
0.002
CI = Confidence interval; IPD = Invasive pneumococcal disease; PCV13 = 13-valent pneumococcal conjugate vaccine; VE = vaccine effectiveness.
aAny child who received PCV7, PCV10 or a mix of either with PCV13 was excluded. bStatistical power: 88%
https://doi.org/10.1371/journal.pone.0183191.t002
Effectiveness of the 13-valent pneumococcal conjugate vaccine in children
PLOS ONE | https://doi.org/10.1371/journal.pone.0183191 August 14, 2017 8 / 15
the distribution of IPD-causing serotypes was very different from that found in Catalonia,
because serotype 3 was not frequent and HIV infection is very frequent; however in non-HIV
infected children, the VE for PCV13-non-PCV7 serotypes was 92% (95% CI, 40–99), very
close to the 95.5% (95% CI, 38.4–99.7) obtained in our study when serotype 3 was excluded
from the analysis.
Table 3. Crude and adjusted effectiveness of the 13-valent pneumococcal conjugate vaccination against IPD caused by PCV13-non-PCV7 sero-
types including and excluding serotype 3 in children aged 7–59 months according to vaccination schedule, number of doses received and age.
Serotypes coverage, vaccination schedule and age
groups
Cases Vaccinated/
N (%)
Controls
Vaccinated/N (%)
Crude VE
(95% CI)
p value Adjusted VE
(95% CI)
p value
PCV13-non-PCV7 serotypesa
1 dose 31/70 (44.3%) 165/253 (65.2%) 56.9% (25.5–
75.1)
0.003 64.2% (31.9–
81.2)
0.002
7–23 months 9/22 (40.9%) 55/86 (63.9%) 59.0% (-4.3–
83.9)
0.06 54.3% (-37.7–
84.8)
0.16b
24–59 months 22/48 (45.8%) 110/167 (65.9%) 55.8% (13.0–
77.6)
0.02 66.9% (28.6–
84.7)
0.005
2 doses before 12 months or 2 doses on or after 12
months or 1 dose on or after 24 months
13/52 (25.0%) 50/138 (36.2%) 46.8% (-21.9–
76.7)
0.14 76.1% (26.3–
92.2)
0.01
7–23 months 5/18 (27.8%) 34/65 (52.3%) 65.6% (-8.7–
89.1)
0.07 89.8% (24.2–
98.6)
0.03
24–59 months 8/34 (23.5%) 16/73 (21.9%) 13.3%
(-175.2–72.7)
0.81 70.4% (-102.3–
95.7)
0.21c
2 doses before 12 months and 1 dose after 12
months
14/53 (26.4%) 93/181 (51.4%) 59.4% (16.6–
80.3)
0.01 70.0% (30.1–
87.1)
0.01
7–23 months 3/16 (18.8%) 21/52 (40.4%) 62.3% (-53.7–
90.7)
0.17 58.7% (-126.9–
92.5)
0.31d
24–59 months 11/37 (29.7%) 72/129 (55.8%) 58.3% (3.5–
82.0)
0.04 71.4% (25.6–
89.0)
0.01
PCV13-non-PCV7 serotypes, excluding serotype 3a
1 dose 9/33 (27.3%) 74/113 (65.5%) 81.3% (53.8–
92.5)
<0.001 95.7% (75.7–
99.3)
<0.001
7–23 months 5/13 (38.5%) 36/51 (70.6%) 70.8% (3.2–
91.2)
0.04 90.1% (34.8–
98.5)
0.02
24–59 months 4/20 (20.0%) 38/62 (61.3%) 89.7% (51.9–
97.8)
0.004 95.3% (64.0–
99.4)
0.003
2 doses before 12 months or 2 doses on or after 12
months or 1 dose on or after 24 months
4/28 (14.3%) 28/67 (41.8%) 76.5% (6.6–
94.1)
0.04 95.5% (38.4–
99.7)
0.02
7–23 months 3/11 (27.3%) 21/36 (58.3%) 66.9% (-49.5–
92.7)
0.15 95.0% (-0.1–
99.8)
0.05e
24–59 months 1/17 (5.9%) 7/31 (22.6%) - - - -
2 doses before 12 months and 1 dose after 12
months
2/26 (7.7%) 39/78 (50.0%) 90.5% (56.6–
97.9)
0.002 97.9% (69.9–
99.9)
0.005
7–23 months 1/9 (11.1%) 15/30 (50.0%) 87.0% (-19.6–
98.6)
0.07 93.1% (2.3–
99.5)
0.04
24–59 months 1/17 (5.9%) 24/48 (50.0%) 92.5% (38.3–
99.1)
0.02 98.5% (58.4–
99.9)
0.01
CI = Confidence interval; IPD = Invasive pneumococcal disease; PCV13 = 13-valent pneumococcal conjugate vaccine; PCV7 = 7-valent pneumococcal
conjugate vaccine; VE = vaccine effectiveness.
aAny child who received only PCV7 or PCV10 was excluded.
Statistical power: b 71%
Statistical power: c 69%
Statistical power: d 52%
Statistical power: e 90%
https://doi.org/10.1371/journal.pone.0183191.t003
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The VE of serotype 19A, the third most frequent serotype in our study, was 86.0% (95% CI,
51.2–99.7) for children receiving1 doses of PCV13 and the results were similar for children
receiving2 doses before 12 months, two doses on or after 12 months or one dose on or after
24 months (85.6%; 95% CI, 6.7–99.8). The fact that the VE confidence intervals in children
receiving2 doses before 12 months and one dose after 12 months included zero might be
explained by the low number of cases. In the study by Miller et al. [21] the VE against serotype
19 was 70% (95% CI, 10–90) and in the study by Van Der Linden et al. [23] it was 88% (95%
CI, 25–99). In the study by Deceuninck et al. [22] the VE observed against serotype 19A was
not statistically-significant (68%; 95% CI, -13 to 91). In the indirect cohort study by Andrews
et al. [27] in England, Wales and Northern Ireland, the VE was 67% (95% CI, 33–84) for this
serotype.
Table 4. Crude and adjusted effectiveness of the 13-valent pneumococcal conjugate vaccination against IPD in children aged 7–59 months by spe-
cific serotype, vaccination schedule, and number of doses received.
Serotypes coverage, vaccination schedule and age
groups
Cases Vaccinated/
N (%)
Controls
Vaccinated/N (%)
Crude VE
(95% CI)
p
value
Adjusted VE
(95% CI)
p
value
Serotype 1a
1 dose 3/14 (21.4%) 30/45 (66.7%) 88.4% (42.6–
97.7)
0.01 89.0% (42.7–
97.9)
0.01
2 doses before 12 months or 2 doses on or after 12
months or 1 dose on or after 24 months
0/11 (0.0%) 6/21 (28.6%) - - - -
2 doses before 12 months and 1 dose after 12 months 1/12 (8.3%) 19/34 (55.9%) 91.9% (31.1–
99.0)
0.02 91.0% (12.2–
99.1)
0.04
Serotype 3a
1 dose 22/37 (59.5%) 91/140 (65.0%) 19.6% (-68.8–
61.7)
0.56 25.9% (-65.3–
66.8)
0.46c
2 doses before 12 months or 2 doses on or after 12
months or 1 dose on or after 24 months
9/24 (37.5%) 22/71 (31.0%) 4.4% (-179.6–
67.3)
0.93 63.3% (-56.2–
91.4)
0.17d
2 doses before 12 months and 1 dose after 12 months 12/27 (44.4%) 54/103 (52.4%) 7.5% (-127.9–
62.4)
0.87 12.8% (-127.9–
66.6)
0.78e
Serotype 14b
1 dose 1/12 (8.3%) 34/46 (73.9%) 95.7% (65.2–
99.5)
0.003 96.9% (70.4–
99.7)
0.003
2 doses before 12 months or 2 doses on or after 12
months or 1 dose on or after 24 months
0/11 (0.0%) 14/26 (53.8%) - - - -
2 doses before 12 months and 1 dose after 12 months 1/12 (8.3%) 20/32 (62.5%) 92.0% (31.1–
99.1)
0.02 94.2% (41.8–
99.4)
0.01
Serotype 19Aa
1 dose 6/14 (42.9%) 35/50 (70.0%) 67.7% (-7.7–
90.3)
0.07 86.0% (51.2–
99.7)
0.01
2 doses before 12 months or 2 doses on or after 12
months or 1 dose on or after 24 months
4/12 (33.3%) 20/35 (57.1%) 68.9% (-38.1–
93.0)
0.12 85.6% (6.7–
99.8)
0.04
2 doses before 12 months and 1 dose after 12 months 1/9 (11.1%) 14/29 (48.3%) 83.3% (-62.3–
98.3)
0.12 84.1% (-97.1–
98.7)
0.15f
CI = Confidence interval; IPD = Invasive pneumococcal disease; VE = vaccine effectiveness.
aAny child who received only PCV7 or PCV10 was excluded.
bAny child who received PCV7, PCV10 or a mix of either with PCV13 was excluded.
Statistical power: c 23%
Statistical power: d 67%
Statistical power: e 7%
Statistical power: f 64%
https://doi.org/10.1371/journal.pone.0183191.t004
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Studies carried out in Western European countries from 2010 to 2014 [28], in Germany
during 1992 to 2014 [29], in the United States during 2004 to 2013 [30], in Portugal from 2012
to 2014 [31] and in England and Wales from 2008 to 2014 [32] have assessed the impact of
PCV13 vaccination on the population and their results confirm those of case-control and indi-
rect cohort studies [28–32]. In most countries that introduced the PCV13, large reductions in
the incidence of IPD have been observed for all vaccine serotypes and for PCV13-non-PCV7
serotypes [28–32]. The reductions were even higher in the cases of serotype 19A in both chil-
dren and adults aged>65 years, confirming herd immunity for this serotype [28–33]. Previous
immunogenicity studies had forecast a high level of effectiveness against this serotype [27,34].
An important finding of our study is that the VE against all PCV13 serotypes and against
PCV13-non-PCV7 serotypes increased for all vaccination schedules and age groups when
serotype 3 cases were excluded from the analysis. Before the PCV13 was licensed, some authors
had suggested that this serotype was less immunogenic than the other PCV13 serotypes [35].
In a Canadian study carried out after complete PCV13 vaccination in children, the level of
opsonophagocitic antibodies was lower against serotype 3 than against other serotypes, sug-
gesting the future level of protection would also be also low [36]. In a study carried out in
Spain and Poland, the immune response against serotype 3 was also clearly lower than that
obtained against other serotypes, particularly serotype 19A [37]. In a double-blinded trial com-
paring the efficacy of the PCV7 with that of PCV13 in preventing S. pneumoniae nasopharyn-
geal colonization, different levels of colonization were found in vaccinated and unvaccinated
children for the serotypes studied, except for serotype 3 [38].
No VE of PCV13 was found for serotype 3 in two case-control studies [21,23] and one indi-
rect cohort study [27]. Significant protection (79.5%; 95% CI, 30.3–93.1) by PCV13 against
serotype 3 was observed only in the matched case-control study by Moore et al. [24], but this
was lower than that found for serotypes 7F (96.5%; 95% CI, 82.7–100) and 19A (85.6%; 95%
CI, 70.6–93.5). As in the present study, Andrews et al. [27] found that the VE of all serotypes
was statistically significant except for serotype 3 (VE 26%, 95% CI, -69 to 68). According to
these authors, the immune correlate of protection of this serotype (2.83 μg/mL, which was
rarely attained with vaccination), was higher than the threshold of 0.35 μg/mL established for
the PCV7 serotypes.
In most western European countries, IPD caused by serotype 3 has been stable or has
increased after the introduction of the PCV13 [28,39]. In Canada and Japan, a similar trend
has been observed [33,40]. Interestingly, the impact study by Moore et al. [30] found no reduc-
tion in the disease incidence caused by serotype 3 in the population, although the same authors
had found that PCV13 was effective against serotype 3 in a case-control study [24]. The study
by Waight et al. in the United Kingdom found some reduction in the incidence of IPD caused
by serotype 3 in all age groups, but in children aged<5 years, the confidence intervals were
very wide (68%; 95% CI, 0.6–89) [32].
In the present study, 44.4% (12/27) of children with IPD caused by serotype 3 had received
2 vaccine doses before 12 months and one dose after 12 months. These results are in accor-
dance with those found in Greece [41], where a third of serotype 3 cases who presented pneu-
monia with pleural effusion were completely vaccinated.
This case-control study, like all observational studies, could be subject to selection and
information biases: selection bias was minimized because controls were matched with cases by
age, sex, risk medical conditions, hospital and date of case admission, and information bias
was minimized because data were obtained in the same way in cases and controls. It seems
unlikely that information bias may invalidate our results because information on the vaccina-
tion status was obtained from health records completed before study recruitment. In addition,
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variables that could confound the results were introduced into the conditional regression anal-
ysis. However, some residual confounding cannot be ruled out.
A strength of the study was the diagnosis by PCR: nearly half the cases would not have been
detected if only cultures had been used and, therefore, the cases included would not have been
representative of hospitalized cases of IPD.
A limitation of the study is that the VE against clinical forms other than pneumonia or
complicated pneumonia and against serotypes other than serotypes 1, 3, 14 and 19A could not
be estimated due to the low number of cases.
In conclusion, we found that the effectiveness of1 doses of PCV13 against IPD caused by
PCV13 serotypes in children aged 7–59 months was good (75.8%) and that the effectiveness
increased for all types of vaccination schedules and age groups when serotype 3 cases were
excluded from the analysis. The VE of1 dose for serotypes 1, 14 and 19A, the most frequent
in our area after serotype 3, is high, ranging between 86% and 96.9%.
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